Treatment with once-weekly alendronate oral jelly compared with once-weekly alendronate oral tablet for Japanese patients with primary osteoporosis: An open-label, prospective, observational study.
Nobukazu OkimotoYukari UemuraToru YoshiokaShinobu AritaHiroshi TsurukamiHajime OtomoSatoshi NishidaTakayuki OgawaKen HiraoSatoshi IkedaHidehiro MatsumotoYoriko TotenYuji KataeYuichi OkazakiTsuyoshi NakagawaAkinori SakaiPublished in: Health science reports (2018)
Once-weekly alendronate oral jelly 35 mg may be a suitable alternative therapeutic agent for primary osteoporosis in Japan.